8th Mar 2005 07:02
GlaxoSmithKline PLC08 March 2005 Issued - 7.00am Tuesday, 8th March 2005, London - LSE Announcement PUBLICATION OF GSK'S FORM 20-F AND REVIEW OF EARNINGS GUIDANCE Today, 8th March 2005, GSK is filing its Annual Report on Form 20-F for 2004with the Securities and Exchange Commission, and this will include updatedreferences to the US Food and Drug Administration's (FDA) actions to haltdistribution of supplies of Paxil CR and Avandamet due to manufacturing issuesat the Group's Cidra, Puerto Rico facility. The Company is working with the FDA to resolve the manufacturing issues withthese products as quickly as possible, although the timing of this and thefinancial impact on the Company's earnings are currently uncertain. Subject to this uncertainty, GSK's published earnings guidance for 2005 remainsEPS percentage growth in the low double-digit range (at constant exchange rates)on an International Financial Reporting Standards basis. S M Bicknell,Company Secretary 8th March 2005 *********** GlaxoSmithKline - one of the world's leading research-based pharmaceutical andhealthcare companies - is committed to improving the quality of human life byenabling people to do more, feel better and live longer. For Companyinformation visit www.gsk.com. Cautionary statement regarding forward-looking statements Under the safe harbor provisions of the US Private Securities Litigation ReformAct of 1995, the Company cautions investors that any forward-looking statementsor projections made by the Company, including those made in this Announcement,are subject to risks and uncertainties that may cause actual results to differmaterially from those projected. Factors that may affect the Group's operationsare described under 'Risk Factors' in the Operating and Financial Review andProspects in the Company's Annual Report on Form 20-F for 2004 which will befiled with the Securities and Exchange Commission today. Enquiries: UK Media enquiries: Philip Thomson (020) 8047 5502 David Mawdsley (020) 8047 5502 Chris Hunter-Ward (020) 8047 5502 US Media enquiries: Nancy Pekarek (215) 751 7709 Mary Anne Rhyne (919) 483 2839 Patricia Seif (215) 751 7709 European Analyst/Investor enquiries: Duncan Learmouth (020) 8047 5540 Anita Kidgell (020) 8047 5542 US Analyst/ Investor enquiries: Frank Murdolo (215) 751 7002 Tom Curry (215) 751 5419 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Glaxosmithkline